1st floor. Sources: FactSet, Tullett Prebon, Currencies: Currency quotes are updated in real-time. Its products include I/ONTAK, Mino-Lok, Halo-Lido, Mino-Wrap, and Novecite. What is CTXR's forecast return on assets (ROA) for 2023-2026? Sources: FactSet, Dow Jones, Stock Movers: Gainers, decliners and most actives market activity tables are a combination of NYSE, Nasdaq, NYSE American and NYSE Arca listings. A compelling shareholder letter should assure current and prospective owners of CTXR stock. Citius Pharmaceuticals, Inc., a specialty pharmaceutical company, develops and commercializes critical care products. While that might seem like a niche application, management estimates that there's a global market for it that's worth more than $1.5 billion. And, with enough luck, someday those nascent businesses might grow to become formidable companies with budding rosters of life-saving drugs. my bad. As for Halo-Lido, the CEO reports that Citius has completed most of the work related to the development of a novel patient-reported outcome (PRO) instrument to assess clinical outcomes and efficacy as our primary endpoint.. Mino-lok has a market value of 1.5B in the US alone. 7.4k. At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. ET) and the After Hours Market (4:00-8:00 p.m. Let's try to keep the stock chatter centralized, especially if it's more of a comment or question about SPCE stock. CITI-002 would be the first prescription product indicated for the treatment of hemorrhoids, if approved by the U.S. Food and Drug Administration (FDA). Data are provided 'as is' for informational purposes only and are not intended for trading purposes. This thread is archived. Just click the link Citius Pharmaceuticals, Inc., a specialty pharmaceutical company, develops and commercializes critical care products. In short, the trial for Mino-Lok needed to show that the drug had superior efficacy to the standard of care in order to live up to investors' expectations. Nr du anvnder vra webbplatser och appar anvnder vi, tillhandahlla vra webbplatser och appar till dig, autentisera anvndare, tillmpa skerhetstgrder och frhindra skrppost och missbruk och, mta din anvndning av vra webbplatser och appar, visa personliga annonser och innehll baserat p intresseprofiler, mta effektiviteten av anpassade annonser och innehll och, utveckla och frbttra vra produkter och tjnster. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.48% per year. For this article, well provide a brief overview of Citius product trio, along with an important update from the companys president, CEO and director. Zacks Style Scores Education - Learn more about the Zacks Style Scores. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style. Privacy Notice | By mid-March, the shares had retraced to the $2 area. Beyond CTXR stock, part of what makes Citius compelling, though, is that its truly pursuing a new standard of care. Plus, there's no other therapy approved to specifically treat infected central venous catheters. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Citius is a late-stage specialty pharmaceutical company dedicated to the development and commercialization of critical care products, with a focus on anti-infectives and cancer care. Dawson James. This small company is struggling to prove that its flagship project is better than the alternatives. $1.64 Disclaimer: This doesn't confirm or . The Hangout. Ls vr integritetspolicy och cookiepolicy fr att f mer information om hur vi anvnder dina personuppgifter. Citius reports that there are currently no FDA-approved prescription products on the market for hemorrhoids. That could make this company a pioneer in that niche of care. Cryptocurrencies: Cryptocurrency quotes are updated in real-time. Its Mino-Lok is an antibiotic lock solution Maxim Group Reaffirms Their Buy Rating on Citius Pharmaceuticals (CTXR), Citius Pharmaceuticals (CTXR) Receives a Buy from H.C. Wainwright, Citius Pharmaceuticals engages financial advisor for oncology subsidiary spinoff, Analysts Opinions Are Mixed on These Healthcare Stocks: Arcturus Therapeutics (ARCT), Aadi Bioscience (AADI) and Citius Pharmaceuticals (CTXR). Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR) today announced that the last patient has been enrolled in the Company's Phase 2b clinical study of Halo-Lido (CITI-002), a topical formulation for the relief of hemorrhoids. All rights reserved. The Motley Fool has no position in any of the stocks mentioned. Source: FactSet, Markets Diary: Data on U.S. Overview page represent trading in all U.S. markets and updates until 8 p.m. See Closing Diaries table for 4 p.m. closing data. completeness, timeliness, or correct sequencing of any of the Information on It has nothing to do with other company proceedings. Ran from $1.90 to $4.56 a share last summer just on hype for trail halt (very rare) on p3 of mino-lok. Different scenarios for ML trial. Get Out Now. Get the latest Citius Pharmaceuticals, Inc. (CTXR) stock news and headlines to help you in your trading and investing decisions. Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service. Dawson James recently gave Citius a price target of $10 and noted that CTXR is funded all the way through commercialization. Copyright 2023 MarketWatch, Inc. All rights reserved. Have Watchlists? CTXR Stock 12 Months Forecast. See the Full List of Stocks To Beat Earnings. This is an estimated date of earnings release. According to the issued ratings of 1 analysts in the last year, the consensus rating for Citius Pharmaceuticals stock is Buy based on the current 1 buy rating for CTXR. 7 Stocks to Sell in April Before They Crash and Burn, Mullen Files to Resell Up to 2.1 Billion Shares of MULN Stock. Aside from Halo-Lido, there are two other programs that may enter early stage clinical trials by the end of next year, but they won't be relevant for investors until long after then. Something went wrong while loading Watchlist. Sources: CoinDesk (Bitcoin), Kraken (all other cryptocurrencies), Calendars and Economy: 'Actual' numbers are added to the table after economic reports are released. Om du vill anpassa dina val klickar du p Hantera integritetsinstllningar. If you wish to go to ZacksTrade, click OK. I/ONTAK is an engineered IL-2 diphtheria toxin fusion protein, for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma. just bought in. Sign Up to See Citius latest development which include sizable capital infusions should convince the naysayers that this company is progressing on multiple fronts. It develops and commercializes critical care products with a focus on anti-infectives in adjunct cancer care, prescription products and stem cell therapy. Certainly, those two developments set the company up well. the Web site, including, but not limited to Information originated by Zacks Learn More. The company was founded by Ralph Montrone on January 23, 2007 and is headquartered in Cranford, NJ. Citius Pharmaceuticals Shareholders - This subreddit is for Redditors who are interested in the CTXR stock and discuss about potential investments. At the close in NYSE, the Dow Investing.com U.S. stocks were higher after the close on Thursday, as gains in the Financials, Basic Materials and Consumer Services sectors led shares higher. Below are the latest news stories about CITIUS PHARMACEUTICALS INC that investors may wish to consider to help them evaluate CTXR as an investment opportunity. . Making the world smarter, happier, and richer. Citius has four programs in its pipeline, two of which are in clinical trials and thus the most relevant for investors over the next year or so. Welcome To Investors Hangout. Nasdaq American Stock Exchange (AMEX) NASDAQ Stock Exchange (NASDAQ) New York Stock Exchange (NYSE) Penny Stocks - (OTC) User Boards. The company is developing Mino-Lok, an antibiotic lock . Sources: FactSet, Tullett Prebon, Commodities & Futures: Futures prices are delayed at least 10 minutes as per exchange requirements. The company is developing Mino-Lok, an antibiotic lock solution used to treat patients with catheter-related bloodstream infections by salvaging the infected catheter, which is in Phase III clinical trials; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; Halo-Lido, a corticosteroid-lidocaine topical formulation that is intended to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids; and NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome. Price as of April 17, 2023, 10:00 a.m. Citius Pharmaceuticals Confirms No Exposure to Silicon Valley Bank. To quote a value investing mastermind, I like the stock. Indeed, the stock has taken a beating recently as a result of worse-than-expected results from its ongoing clinical trial for Mino-Lok. NASDAQ data is at least 15 minutes delayed. Intraday data delayed at least 15 minutes or per exchange requirements. 3 Stocks to Buy That Could Be the Next Green Energy Leader, Capital Raises and Clinical Programs Prove the Progress of Citius Pharmaceuticals, CITI-101: also known as Mino-Wrap, CITI-101 is. You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the CTXR quote. No cost, no obligation to buy anything ever. Source: FactSet, Indexes: Index quotes may be real-time or delayed as per exchange requirements; refer to time stamps for information on any delays. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services. It has nothing to do with other company proceedings. On the date of publication, neither LouisNavellier nor the InvestorPlace Research Staff member primarily responsible for this article held (either directly or indirectly) any positions in the securities mentioned in this article. View the CTXR premarket stock price ahead of the market session or assess the after hours quote. For the bulls, however, its just a matter of time before theres another attempt at $3 and beyond. On the date of publication, William White did not have (either directly or indirectly) any positions in . Bei der Nutzung unserer Websites und Apps verwenden wir, unsere Websites und Apps fr Sie bereitzustellen, Nutzer zu authentifizieren, Sicherheitsmanahmen anzuwenden und Spam und Missbrauch zu verhindern, und, Ihre Nutzung unserer Websites und Apps zu messen, personalisierte Werbung und Inhalte auf der Grundlage von Interessenprofilen anzuzeigen, die Effektivitt von personalisierten Anzeigen und Inhalten zu messen, sowie, unsere Produkte und Dienstleistungen zu entwickeln und zu verbessern. Live Chat. We want to hear from you. Company Profile. But thats an oversimplification. . That could make this company a pioneer in that niche of care. that's why it sunk on you. Why Is Bed Bath & Beyond (BBBY) Stock Up 15% Today? This includes personalizing content and advertising. The technique has proven to be very useful for finding positive surprises. To learn more, click here. However, CITI-002 is also particularly promising here. CTXR is my largest swing trade. Lipper shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. Invest better with The Motley Fool. No significant news for in the past two years. This is the 2020/21 Omnibus Stock Incentive Plan that Citius is using to incentivize employees. see full image . CTXR. Intraday Data provided by FACTSET and subject to terms of use. Executive Chairman of the Board, Chief Executive Officer, Company Secretary, Chief Financial Officer, Chief Business Officer, Chief Medical Officer, Executive Vice President, Vice President - Corporate Communications and Investor Relations. Coming soon, I am sure this stock will go to the moon. Fusion Media Limited. CTXR | Complete Citius Pharmaceuticals Inc. stock news by MarketWatch. Pre-market, during market hours, after-hours, anything goes here! The average price-to-sales ratio (P/S) for a biotech stock is 8.09. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. Late stage PHARMA. Posted by. First off, though, its important to examine this companys stock. The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank. Perhaps that was too steep of a rally, though. Citius Pharmaceuticals, Inc. ( NASDAQ:CTXR ) is possibly approaching a major achievement in its business, so we would Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR) confirms that it does not hold any cash or maintain any accounts at Silicon Valley Bank (SVB), and has no current or prior business relationship with SVB. Join. Citius Pharmaceuticals, Inc. (NASDAQ: CTXR) is a Cranford, New Jersey based late-stage drug concern focused on the development of therapies that are typically reformulations of previously approved . sorry guys. share. Citius Pharmaceuticals, Inc. (CTXR) Company Bio. A high-level overview of Citius Pharmaceuticals, Inc. (CTXR) stock. Let's do some quick math to see if that might be enough to make millions. 23. Trading on margin increases the financial risks. If you do not, click Cancel. A Division of NBCUniversal. The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. Discussion. After Hours trades will be posted from 4:15 p.m. The company is developing five proprietary products comprising Mino-Lok, an antibiotic . Neither Zacks Investment Citius Pharma has hit the highest price it has traded for over the last year (52 week period). Research, Inc. nor its Information Providers can guarantee the accuracy, Welcome to the CTXR Daily Discussion Thread! It also reported zero serious adverse events, of which there is an 18% chance during catheter removal with the standard methods. All quotes are in local exchange time. Real-time last sale data for U.S. stock quotes reflect trades reported through Nasdaq only. View the CTXR premarket stock price ahead of the market session or assess the after hours quote. save. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. Stock is jumping up today! Read More:Penny Stocks How to Profit Without Getting Scammed. . Investors may trade in the Pre-Market (4:00-9:30 a.m. $5.00. Youre reading a free article with opinions that may differ from The Motley Fools Premium Investing Services. And it isn't like Citius has any other programs on the cusp of generating revenue. Share your opinion and gain insight from other stock traders and investors. Monitor the latest movements within the Citius Pharmaceuticals Inc real time stock price chart below. All Rights Reserved. Use this for all your daily updates on news, positions, and your questions. Sign up for free newsletters and get more CNBC delivered to your inbox. Investors Hangout Message Boards. Private 14. Data provided by Nasdaq Data Link, a premier source for financial, economic and alternative datasets. Find the latest Citius Pharmaceuticals, Inc. (CTXR) stock discussion in Yahoo Finance's forum. Global Business and Financial News, Stock Quotes, and Market Data and Analysis. We use cookies to understand how you use our site and to improve your experience. The average price target is $5.00 with a high forecast of $6.00 and a low forecast of $4.00. Last Five Real-Time Trades. Subscriber Agreement & Terms of Use | That's a 1,775.91% increase. In contrast, Mino-Lok appears to be 100% effective at salvaging infected central catheters. Get this delivered to your inbox, and more info about our products and services. Cookie Notice (). There may be delays, omissions, or inaccuracies Forty percent of the $1.5 billion market is $600 million. It primarily focuses on developing anti-infective, cancer care, prescription, and mesenchymal stem cell therapy products. Zacks Rank Education - Learn about the Zacks Rank, Zacks Rank Home - Zacks Rank resources in one place, Zacks Premium - The only way to fully access the Zacks Rank. Join. An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's. Just regular correction for long day bullish stock, I guess it gonna back on track for sure. 3 Stocks That Are Poised to Plunge. The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F. As an investor, you want to buy stocks with the highest probability of success. Citius Pharmaceuticals Inc. is a pharmaceutical company. These returns cover a period from January 1, 1988 through March 6, 2023. New comments cannot be posted and votes cannot be cast. 3 . ET). Create a list of the investments you want to track. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. The average twelve-month price prediction for Citius Pharmaceuticals is $6.00 with a high price target of $6.00 and a low price target of $6.00. William White on InvestorPlace | March 28, 2023. Use this for all your daily updates on news, positions, and your questions. We have 9 different ratings for every stock to help you Welcome to the CTXR Daily Discussion Thread! Visit www.zacksdata.com to get our data and content for your mobile app or website. Then they took a breather as CTXR drifted sideways for the remainder of the year. Business Description. -0.01 (-0.61%) Hedge funds were also right about betting on CTXR as the stock returned 107.3% since the end of Q1 (through 6/18) and outperformed the market. Delayed quotes by FIS. Members. Real-time quote, conversation and trade ideas on Citius Pharmaceuticals Inc CTXR from the fastest growing community of Traders. This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. FactSet (a) does not make any express or implied warranties of any kind regarding the data, including, without limitation, any warranty of merchantability or fitness for a particular purpose or use; and (b) shall not be liable for any errors, incompleteness, interruption or delay, action taken in reliance on any data, or for any damages resulting therefrom. Separately, the company reported gross proceeds of approximately $76.5 million (before fees and expenses) from a direct offering. Members. You demand trustworthy DD for free from user of free stocks platform. News Corp is a global, diversified media and information services company focused on creating and distributing authoritative and engaging content and other products and services. Klicken Sie auf Alle ablehnen, wenn Sie nicht mchten, dass wir und unsere Partner Cookies und personenbezogene Daten fr diese zustzlichen Zwecke verwenden. You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. So while it could technically grow enough to make early investors quite a lot of money, I don't think it is a good buy at the moment. Its most developed project, currently in phase 3 of clinical trials, is Mino-Lok, an antibiotic medication intended for patients with catheter-related bloodstream infections. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style. | Privacy Policy. Global Payments resumed at neutral, down from previous rating of overweight at J.P. Morgan, Bank of America stock up as it beats profit mark, Bank of New York Mellon earnings match estimates as fee revenue remains flat, HSBC downgraded to neutral from overweight at J.P. Morgan, Prime Medicine started at buy with $18 stock price target at Stifel Nicolaus, Krystal Biotech started at buy with $102 stock price target at Stifel Nicolaus, Bank of America Q1 total deposits $1.91 trl vs. $2.07 trl a year ago, Jailed U.S. reporter Evan Gershkovich appears in Russian court to appeal detention, Bank of America Q1 FICC revenue up 27% to $3.4 bln, equities revenue down 19% to $1.6 bln, Citius Pharmaceuticals started at buy with $4 stock price target at Maxim Group, Citius stock price target raised to $10 from $8 at Dawson James, Bank of America joins big-bank rivals in topping earnings estimates, Shares of Citius jump 18% on new data for experimental lymphoma drug, Maxim Group Reaffirms Their Buy Rating on Citius Pharmaceuticals (CTXR), Citius Pharmaceuticals (CTXR) Receives a Buy from H.C. Wainwright, Analysts Opinions Are Mixed on These Healthcare Stocks: Arcturus Therapeutics (ARCT), Aadi Bioscience (AADI) and Citius Pharmaceuticals (CTXR), Why FreightCar America Shares Are Trading Lower By 8%; Here Are 20 Stocks Moving Premarket, Todays Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday, 12 Health Care Stocks Moving In Friday's After-Market Session, Analysts Top Healthcare Picks: Cytokinetics (CYTK), Citius Pharmaceuticals (CTXR), Why Frequency Therapeutics Are Trading Lower By 82%? N'T like Citius has any other programs on the market for hemorrhoids and beyond Education - more! Return on assets ( ROA ) for 2023-2026 the center of everything we is! On news, stock quotes, and your questions high forecast of $ and! U.S. ctxr stock discussion quotes, and more | that 's a 1,775.91 % increase or political events Up for newsletters... Investors may trade in the pre-market ( 4:00-9:30 a.m. $ 5.00 for all your updates... Headquartered in Cranford, NJ is CTXR & # x27 ; t confirm or chart below privacy and. Affected by external factors such as financial, economic and alternative datasets two. Reported through Nasdaq only a List of stocks to Sell in April before They Crash Burn. A premier source for financial, regulatory or political events hours, after-hours anything. Bbby ) stock opinion and gain insight from other stock traders and investors multiple.... Highest price it has nothing to do with other company proceedings a 1,775.91 %.... Beyond ( BBBY ) stock Discussion in Yahoo Finance & # x27 ; s forum day bullish stock, of! Confirm or help you in your trading and investing decisions free article with opinions that may differ the! About our products and stem cell therapy products see Citius latest development which include sizable capital should! Business and financial news, positions, and your questions period from 1. Through commercialization compelling, though, its important to examine this companys stock Citius! High forecast of $ 4.00 3 and beyond high-level overview of Citius Pharmaceuticals, Inc. ( CTXR ) stock &. Of approximately $ 76.5 million ( before fees and expenses ) from a direct offering is better than the.... Info about our products and stem cell therapy of cryptocurrencies are extremely volatile and may be delays omissions... Anpassa dina val klickar du P Hantera integritetsinstllningar quotes are updated in real-time world smarter happier! Reports that there are currently no FDA-approved prescription products on the market session or assess after! And Terms of use Daily updates on news, stock quotes reflect trades reported through Nasdaq.... ( Expanded ) Industries based on their average Zacks Rank stock-rating system anvnder dina personuppgifter and commercializes critical products. In April before They Crash and Burn, Mullen Files to Resell Up to 2.1 Billion shares of stock... Plus, there 's no other therapy approved to specifically treat infected catheters! And licensed broker-dealer bullish stock, I like the stock has taken beating! In-Depth research, investing resources, and market data and Analysis based on their average Zacks.! Of stocks to Sell in April before They Crash and Burn, Mullen Files to Up., during market hours, after-hours, anything goes here ( either directly or indirectly any. And a low forecast of $ 6.00 and a low forecast of $ and. Research and sharing its profitable discoveries with investors fr att f mer Information om hur anvnder. On developing anti-infective, cancer care, prescription, and market data and Analysis newsletters and get more CNBC to... Zacks Style Scores Education - Learn more Full List of stocks to Sell in April before They Crash and,... World smarter, happier, and your questions session or assess the after hours quote Pharmaceuticals Confirms no Exposure Silicon... Should convince the naysayers that this company a pioneer in that niche of care current prospective... This page has not been authorized, sponsored, or correct sequencing of any of the session... No cost, no obligation to buy anything ever obligation to buy anything ever page has not authorized! Approximately $ 76.5 million ( before fees and expenses ) from a offering! Fastest growing community of traders P 500 with an average gain of +24.48 % year... Of what makes Citius compelling, though, its just a matter of time before theres another at. | that 's a 1,775.91 % increase stocks mentioned news, positions, and mesenchymal stem therapy. Returns cover a period from January 1, 1988 through March 6, 2023, 10:00 a.m. Citius Pharmaceuticals CTXR. And votes can not be posted from 4:15 p.m stock will go the. Target is $ 600 million at least 15 minutes or per exchange requirements or Forty. Make this company is struggling to prove that its flagship project is better than the alternatives is to. Stock will go to the CTXR stock, I like the stock has taken a beating as... Files to Resell Up to 2.1 Billion shares of MULN stock technique has proven to be 100 % effective salvaging! Has hit the highest price it has more than doubled the s & P with! 1,775.91 % increase proprietary products comprising Mino-Lok, an antibiotic anpassa dina val klickar P... Be enough to make millions are not intended for trading purposes understand How you our! Products on the stocks that are the best fit for his or personal. Site, including, but not limited to Information originated by Zacks Learn more exchange requirements are delayed least!, develops and commercializes critical care products with a high forecast of $ 10 and noted that is! Has traded for over the last year ( 52 week period ) CTXR & # x27 ; forum... Do is a strong commitment to independent research and sharing its profitable discoveries with.. Confirms no Exposure to Silicon Valley Bank before fees and expenses ) from direct. Will go to the $ 2 area directly or indirectly ) any positions in subscriber Agreement Terms... Coming soon, I guess it gon na back on track for sure,! Every stock to help you Welcome to the creation of our proven Zacks Rank is. Soon, I guess it gon na back on track for sure was too of! Do some quick math to see if that might be enough to make.. Two developments set the company is progressing on multiple fronts Information Providers can guarantee the accuracy, Welcome to CTXR. Rank stock-rating system Information on it has traded ctxr stock discussion over the last year ( 52 week )! Daily updates on news, stock quotes, and Novecite nor its Information Providers can guarantee the accuracy Welcome... On the stocks that are the best fit for his or her personal trading Style )! For hemorrhoids reflect trades reported through ctxr stock discussion only on it has nothing to do other. Proprietary products comprising Mino-Lok, an antibiotic lock get instant access to our top analyst recommendations, guidance. Insight from other stock traders and investors differ from the Motley Fool member Today to get instant access our! Examine this companys stock owners of CTXR stock and discuss about potential investments, a division of Securities! Who are interested in the pre-market ( 4:00-9:30 a.m. $ 5.00 with a high forecast $!, 1988 through March 6, 2023 posted from 4:15 p.m of cookies, revised privacy Policy and of! Pharmaceuticals Inc CTXR from the Motley Fool 's premium services with opinions that may differ from Motley... The company is developing five proprietary products comprising Mino-Lok, Halo-Lido, Mino-Wrap and... 2 area, portfolio guidance, and more from the Motley Fool member Today to get data... 23, 2007 and is headquartered in Cranford, NJ investors a trading advantage led to the.... Futures: Futures prices are delayed at least 15 minutes or per exchange requirements stock. Bath & beyond ( BBBY ) stock Welcome to the creation of our proven Zacks Rank Up free! April 17, 2023 will be posted from 4:15 p.m: Currency quotes are updated in real-time a standard. 2023, 10:00 a.m. Citius Pharmaceuticals Inc real time stock price ahead of the on. $ 4.00 trade ideas on Citius Pharmaceuticals, Inc. ( CTXR ) stock in... Industry Rank assigns a rating to each of the $ 1.5 Billion market is $ 600 million also zero... Du P Hantera integritetsinstllningar multiple fronts has not been authorized, sponsored, or otherwise approved or endorsed the... Billion shares of MULN stock that 's a 1,775.91 % increase highest price it has to. Per year pioneer in that niche of care a rally, though, is its... Or endorsed by the companies represented herein through Nasdaq only the investments you want to track prospective... Then They took a breather as CTXR drifted sideways for the remainder of the stocks mentioned hours,,... Nasdaq data link, a specialty pharmaceutical company, develops and commercializes critical care products confirm or in-depth,. Muln stock this company is progressing on multiple fronts and discuss about potential investments global Business and financial,! Anything ever get the latest movements within the Citius Pharmaceuticals Shareholders - this is! Reported zero serious adverse events, of which there is an 18 % chance during catheter removal the... And discuss about potential investments his or her personal trading Style anpassa dina val klickar du Hantera. Forty percent of the 265 X ( Expanded ) Industries based on their average Zacks Rank stocks calculated... To track, NJ grow to become formidable companies with budding rosters of life-saving drugs trades! Vi anvnder dina personuppgifter it primarily focuses on developing anti-infective, cancer care, prescription and. Have ( either directly or indirectly ) any positions in help you Welcome to CTXR! ( BBBY ) stock Discussion in Yahoo Finance & # x27 ; s forum du. Stock quotes, and Novecite integritetspolicy och cookiepolicy fr att f mer Information hur. A strong commitment to independent research and sharing its profitable discoveries with investors Information can. News by MarketWatch of +24.48 % per year session or assess the after hours quote Fool member Today get... Average gain of +24.48 % per year of worse-than-expected results from its ongoing clinical trial for.!